Takeda submits NDA for Actos replacement as DPP-IV pipeline heats up

Share this article:
Takeda Pharmaceutical has submitted a new DPP-IV diabetes drug candidate -- Alogliptin -- in hopes the drug will replace its major earner Actos which loses patent protection in 2011.

"We are hoping Alogliptin to boost our diabetes franchise, which is a very important field for us," said Takeda spokesman Toshiyuki Ikeuchi in a statement.

The approval process is expected to take about a year.

Nomura Securities senior analyst said he expects Alogliptin sales to reach ($2.8 billion) a year during the peak years, which is anticipated about  five years after launch. “I see the drug as very promising,” Ryoichi said.

Alogliptin, or SYR-322, is in a new class of oral agents for the treatment of type 2 diabetes, called DPP-4 inhibitor, regulating blood glucose levels, and the class also includes Merck & Co's Januvia and Novartis AG's Galvus.

“Safety evaluation is very strict for drugs in this category. There are some possibilities for the approval process would not go smoothly,” Nomura's Ryoichi said.

Studies have found evidence that certain diabetes drugs, including Takeda's Actos and Glaxo SmithKline's Avandia, raise the risk of heart failure.

Bear Stearns analyst John Boris wrote in a note to investors that there is a risk
of delays in the Alogliptin NDA.

“Although we have not seen Phase III data presented for Alogliptin, we found five phase III studies initiated in January 2006 out of nine phase III studies listed at ClinicalTrials.gov… these five studies do not exclude patients with renal impairment…there is a risk of Takeda not gathering enough exposures in all necessary ranges of renal insufficiency. FDA could also have a strict requirement
for a study targeting specifically the renally impaired population,” Boris wrote.

Meanwhile, the race to develop DPP-IV Inhibitors is heating up.

According to Boris, there are 16 other programs targeting DPP-IVs, indicating potentially strong competition in this class in the future.

For a closer look see chart below.

DPP-IV Inhibitors: Stage of Pipeline Development

Drug          Company Stage of Development

Galvus (Vildagliptin)


Approvable in US with resubmission in 2009 or later; EU approved but not launched


Bristol-Myers Squibb/AstraZeneca

Phase III; mid-2008 filing expected

SYR-322 (Alogliptin)

SYR-322 (Alogliptin)

Phase III


Merck KGaA/Glenmark

Phase II



Phase II


OSI Pharmaceuticals

Phase II (Assessing outlicensing or discontinuing the program)



Phase II



Phase II



Phase II

BI 1356

Boehringer Ingelheim

Phase II



Phase I



Phase I



Phase I


Taisho Pharmaceutical

Phase I

ALS 2-0426


Phase I


LG Life Sciences

Phase I



Phase I


Arisaph Pharmaceuticals


S 40010



-Courtesy Bear Stearns
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...